WO2000052147A9 - Bacterial prolyl peptidases and methods of use - Google Patents
Bacterial prolyl peptidases and methods of useInfo
- Publication number
- WO2000052147A9 WO2000052147A9 PCT/US2000/005551 US0005551W WO0052147A9 WO 2000052147 A9 WO2000052147 A9 WO 2000052147A9 US 0005551 W US0005551 W US 0005551W WO 0052147 A9 WO0052147 A9 WO 0052147A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptidase
- prolyl
- seq
- tripeptidyl
- active
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 title claims description 68
- 102000035195 Peptidases Human genes 0.000 title description 99
- 108091005804 Peptidases Proteins 0.000 title description 99
- 235000019833 protease Nutrition 0.000 title description 93
- 230000001580 bacterial effect Effects 0.000 title description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 184
- 101710161610 Prolyl tripeptidyl peptidase Proteins 0.000 claims abstract description 179
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 132
- 229920001184 polypeptide Polymers 0.000 claims abstract description 105
- 150000001413 amino acids Chemical class 0.000 claims abstract description 83
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 52
- 230000003024 amidolytic effect Effects 0.000 claims abstract description 48
- 239000012634 fragment Substances 0.000 claims abstract description 38
- 230000004048 modification Effects 0.000 claims abstract description 36
- 238000012986 modification Methods 0.000 claims abstract description 36
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 29
- 230000007017 scission Effects 0.000 claims abstract description 29
- 241000894006 Bacteria Species 0.000 claims abstract description 21
- 230000012010 growth Effects 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 68
- 125000003729 nucleotide group Chemical group 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 239000003112 inhibitor Substances 0.000 claims description 34
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims description 23
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims description 22
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 20
- 239000007995 HEPES buffer Substances 0.000 claims description 20
- 230000000295 complement effect Effects 0.000 claims description 20
- 230000000890 antigenic effect Effects 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 230000002163 immunogen Effects 0.000 claims description 12
- 201000001245 periodontitis Diseases 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 7
- 208000028169 periodontal disease Diseases 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000007565 gingivitis Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 description 78
- 229940024606 amino acid Drugs 0.000 description 76
- 102000004190 Enzymes Human genes 0.000 description 49
- 108090000790 Enzymes Proteins 0.000 description 49
- 229940088598 enzyme Drugs 0.000 description 49
- 230000000694 effects Effects 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108091026890 Coding region Proteins 0.000 description 22
- 230000003197 catalytic effect Effects 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 19
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 19
- 239000000758 substrate Substances 0.000 description 18
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 17
- 235000004400 serine Nutrition 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 238000000746 purification Methods 0.000 description 14
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 13
- 230000007062 hydrolysis Effects 0.000 description 13
- 238000006460 hydrolysis reaction Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 108700026244 Open Reading Frames Proteins 0.000 description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 12
- 239000012528 membrane Substances 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 108010016626 Dipeptides Proteins 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 9
- 108091020100 Gingipain Cysteine Endopeptidases Proteins 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 7
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 7
- 235000011130 ammonium sulphate Nutrition 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 7
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 6
- 208000005888 Periodontal Pocket Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- SUGXUUGGLDCZKB-UHFFFAOYSA-N 3,4-dichloroisocoumarin Chemical compound C1=CC=C2C(Cl)=C(Cl)OC(=O)C2=C1 SUGXUUGGLDCZKB-UHFFFAOYSA-N 0.000 description 5
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 229940122344 Peptidase inhibitor Drugs 0.000 description 5
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- -1 glycylprolyl Chemical group 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 229910000160 potassium phosphate Inorganic materials 0.000 description 5
- 235000011009 potassium phosphates Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 108010087765 Antipain Proteins 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 108010005843 Cysteine Proteases Proteins 0.000 description 4
- 102000005927 Cysteine Proteases Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000006167 equilibration buffer Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
- 108010052968 leupeptin Proteins 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000008057 potassium phosphate buffer Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- AGRIQBHIKABLPJ-UHFFFAOYSA-N 1-Pyrrolidinecarboxaldehyde Chemical compound O=CN1CCCC1 AGRIQBHIKABLPJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000589566 Elizabethkingia meningoseptica Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 241000986839 Porphyromonas gingivalis W83 Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000009435 amidation Effects 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- UTXSFKPOIVELPQ-SFHVURJKSA-N benzyl n-[2-[(2s)-2-[(4-nitrophenyl)carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamate Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)[C@H]1N(C(=O)CNC(=O)OCC=2C=CC=CC=2)CCC1 UTXSFKPOIVELPQ-SFHVURJKSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011098 chromatofocusing Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108010072257 fibroblast activation protein alpha Proteins 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 230000033444 hydroxylation Effects 0.000 description 3
- 238000005805 hydroxylation reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 125000003473 lipid group Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 238000002887 multiple sequence alignment Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108010089414 Anaphylatoxins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000912205 Homo sapiens Cystatin-C Proteins 0.000 description 2
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 2
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 2
- 108700015930 Prolyl Oligopeptidases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000049632 human CST3 Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 108010032563 oligopeptidase Proteins 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 210000002379 periodontal ligament Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
- KYRVEVYREUUAKH-PPHPATTJSA-N (2s)-n-(4-nitrophenyl)pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC([N+](=O)[O-])=CC=C1NC(=O)[C@H]1NCCC1 KYRVEVYREUUAKH-PPHPATTJSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102100032488 Acylamino-acid-releasing enzyme Human genes 0.000 description 1
- 108010061216 Acylaminoacyl-peptidase Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102100032126 Aminopeptidase B Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 241000252073 Anguilliformes Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101710097732 Bradykinin-related peptides Proteins 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101000809889 Dinoponera quadriceps M-poneratoxin-Dq4e Proteins 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- LTLYEAJONXGNFG-DCAQKATOSA-N E64 Chemical compound NC(=N)NCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O LTLYEAJONXGNFG-DCAQKATOSA-N 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101500027773 Homo sapiens Dentin phosphoprotein Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 102000003667 Serine Endopeptidases Human genes 0.000 description 1
- 108090000083 Serine Endopeptidases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 108090000449 aminopeptidase B Proteins 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010041102 azocasein Proteins 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 101150115781 prtT gene Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000003033 spasmogenic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- Porphyromonas gingivalis (formerly Bacteroides gingivalis) is an obligately anaerobic bacterium which is implicated in periodontal disease.
- P. gingivalis produces several distinct proteolytic enzymes, many of which are recognized as important virulence factors.
- a number of physiologically significant proteins, including collagen, fibronectin, immunoglobulins, complement factors C3, C4, C5, and B, lysozyme, iron-binding proteins, plasma proteinase inhibitors, fibrin and fibrinogen, and factors of the plasma coagulation cascade system, are hydrolyzed by P. gingivalis proteases.
- Broad proteolytic activity plays a role in the evasion of host defense mechanisms and the destruction of gingival connective tissue in progressive periodontitis.
- Periodontitis is characterized by acute tissue degradation promoted by collagen digestion and a vigorous inflammatory response characterized by excessive neutrophil infiltration.
- Gingival crevicular fluid accumulates in periodontitis as periodontal tissue erosion progresses at the foci of the infection, and numerous plasma proteins are exposed to proteinases expressed by the bacteria at the injury site.
- Neutrophils are recruited to the gingiva, in part, by the humoral chemotactic factor C5a.
- the complement components C3 and C5 are activated by complex plasma proteases with "trypsin-like" specificities called convertases.
- the human plasma convertases cleave the ⁇ -chains of C3 and C5 at a specific site generating biologically active factors known as anaphylatoxins (i.e.
- the anaphylatoxins are potent proinflammatory factors exhibiting chemotactic and/or spasmogenic activities as well as promoting increased vascular permeability.
- the larger products from C3 and C5 cleavage i.e. C3b and C5b participate in functions including complement cascade activation, opsonization, and lytic complex formation.
- gingipain K (also referred to as "Lys-gingipain”), an enzyme which cleaves Lys-Xaa peptide bonds, degrades fibrinogen. This may add to a bleeding on probing tendency associated with periodontitis.
- the presence of a hemagglutinin/adhesion domain in the non covalent multiprotein complexes of RgpA and gingipain K suggests participation of these enzymes in the binding of P. gingivalis to extracellular matrix proteins which may facilitate tissue invasion by this pathogen.
- glycylprolyl peptidase (DPP IV) was found to be associated with bacterial surfaces and two molecular mass forms of this peptidase have been described. This enzyme has also been shown to possess the ability to hydrolyze partially degraded type I collagen, releasing the Gly-Pro dipeptide, and it was suggested that, in collaboration with collagenase, glycylprolyl peptidase may contribute to the destruction of the periodontal ligament (Abiko, Y., et al. (1985) J.Dent. Res. 64, 106-111). In addition to this potential pathological function, glycylprolyl peptidase may also play a vital role in providing P.
- the present invention is directed to an isolated prolyl tripeptidyl- peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids.
- the isolated prolyl tripeptidyl- peptidase, active analog, active fragment, or active modification thereof is isolated from P. gingivalis.
- amidolytic activity is determined with a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1 : 1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
- the peptide cleaved by the isolated prolyl tripeptidyl- peptidase can include the sequence of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:l 1, H-Ala-Arg-Pro-Ala-D- Lys-amide, SEQ LD NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ LD NO:25, or SEQ ID NO:37.
- the amino acid sequence of the isolated prolyl tripeptidyl- peptidase can include the amino acid sequence GXSXXG (SEQ ID NO: 39), the amino acid sequence GXSXGG (SEQ LD NO:40), or the amino acid sequence of
- Another aspect of the invention is an isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids.
- the invention is also directed to an isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ LD NO:30.
- An alternative aspect of the invention is an isolated nucleic acid fragment encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids.
- the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1 : 1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
- the nucleic acid fragment can have a nucleotide sequence comprising SEQ ID NO:38.
- a complement of the nucleic acid fragment can hybridize to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.
- Another aspect of the invention is an isolated nucleic acid fragment encoding a polypeptide that includes an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
- the invention is also directed at a method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, including identifying a molecule that inhibits the amidolytic activity of the prolyl-tripeptidyl peptidase.
- the inhibitor is identified by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.
- An aspect of the invention is a method of reducing growth of a bacterium.
- This method includes inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, or a prolyl dipeptidyl- peptidase, active analog, active fragment, or active modification thereof.
- the method includes contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase.
- the method can be used to protect an animal from a periodontal disease caused by P. gingivalis including administering to the animal the inhibitor.
- the disease can be selected from the group consisting of gingivitis and periodontitis.
- the inhibitor can be administered by a method selected from the group consisting of subgingival application and controlled release delivery.
- Another aspect of the invention is an immunogenic composition including an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl- peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids.
- the prolyl tripeptidyl- peptidase:target polypeptide ratio is at least about 1 :1 to no greater than about 1 : 10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
- the immunogenic composition can include an adjuvant.
- the invention is also directed to a composition including an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.
- Additional aspects of the invention include a dipeptidyl peptidase having an amino acid sequence including SEQ ID NO:43, SEQ LD NO:44, or SEQ ID NO:45. Definitions
- Polypeptide refers to a polymer of amino acids and does not refer to a specific length of a polymer of amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and enzyme are included within the definition of polypeptide. This term also includes post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like.
- a polypeptide can be produced by an organism, or produced using recombinant techniques, or chemically or enzymatically synthesized.
- Proteinase proteinsase
- protease enzymes that catalyze the hydrolysis of peptide bonds in a polypeptide.
- amide bond is a covalent bond between the alpha-amino group of one amino acid and the alpha-carboxyl group of another amino acid.
- Peptidase inhibitor proteinase inhibitor
- proteease inhibitor and “inhibitor” all refer to molecules that inhibit a peptidase that catalyzes the hydrolysis of peptide bonds in a polypeptide.
- isolated means that a polypeptide or a nucleic acid fragment has been either removed from its natural environment, produced using recombinant techniques, or chemically or enzymatically synthesized.
- the polypeptide or nucleic acid fragment is purified, i.e., essentially free from any other polypeptides or nucleic acid fragments and associated cellular products or other impurities.
- Amidolytic activity refers to the ability of a polypeptide to catalyze the hydrolysis of at least one peptide bond in a polypeptide.
- the term “cleavage” can also be used to refer to the hydrolysis of a peptide bond in a polypeptide.
- Prolyl-tripeptidyl peptidase and “PTP” refer to a polypeptide having a particular "amidolytic activity”.
- a “prolyl-tripeptidyl peptidase” is able to hydrolyze the peptide bond between the proline and the Yaa residues in a target polypeptide with the general formula NH 2 -Xaa-Xaa-Pro- Yaa-(Xaa) n (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or modified amino acid except proline, and the ⁇ -amino of the amino terminal residue is not blocked.
- a “prolyl tripeptidyl-peptidase” does not have to cleave all members of the target peptide.
- the term "natural amino acid” refers to the 20 amino acids typically produced by a cell.
- modified amino acid refers to, for instance, acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.
- a "target polypeptide” is a polypeptide that is the potential substrate of the amidolytic activity of a prolyl tripeptidyl-peptidase.
- An active analog, active fragment, or active modification of a polypeptide of the invention is one that has amidolytic activity by hydrolysis of a peptide bond present in the target polypeptide as described herein. Active analogs, fragments, and modifications are described in greater detail herein.
- Nucleic acid fragment refers to a linear polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides, and includes both double- and single-stranded DNA and RNA.
- a nucleic acid fragment may include both coding and non-coding regions that can be obtained directly from a natural source (e.g., a microorganism), or can be prepared with the aid of recombinant or synthetic techniques.
- a nucleic acid molecule may be equivalent to this nucleic acid fragment or it can include this fragment in addition to one or more other nucleotides or polynucleotides,
- the nucleic acid molecule of the invention can be a vector, such as an expression of cloning vector.
- Percentage amino acid identity refers to a comparison of the amino acids of two polypeptides as described herein.
- FIGURES Fig. 1 Purification of the prolyl tripeptidyl peptidase from the acetone precipitate of the P. gingivalis cell extracts. Absorbance at 280 nm (open triangles), amidolytic activity against H-Ala-Phe-Pro-pNA (closed diamonds), and H-Gly-Pro-pNA (closed circles), (a) Separation of PTP-A on hydroxyapatite. (b) Separation of PTP-A on Phenyl-Sepharose HP. (c) Separation of PTP-A on MonoQ FPLC. (d) Chromatofocusing of PTP-A on Mono-P.
- Fig.2 SDS -PAGE of fractions from purification of PTP-A and the autoradiography of the purified enzyme.
- Lane a molecular mass markers (phosphorylase B, 97 kDa; bovine serum albumin, 68 kDa; ovalbumin, 43 kDa; carbonic anhydrase, 30 kDa; soybean trypsin inhibitor, 20 kDa; ⁇ -lactalbumin, 14 kDa); lane b, acetone precipitate from Triton X-100 extract of P.
- lane c hydroxyapatite column eluate; lane d, Phenyl-Sepharose column eluate; lane e, MonoQ column eluate; lanef, purified PTP-A from MonoP column wash; lane g, autoradiograph of 3 H-DFP labeled enzyme exposed for 96 h to X-ray film. All samples were reduced and boiled prior to PAGE analysis.
- PTP-A PTP-A
- Pg-DPP DPP from P. gingivalis (Kiyama, M., et al., (1998) Bioch Bioph. Acta 1396. 39-46) containing an amino-terminal sequence corrected according to the P. gingivalis W83 genome data available from The Institute of Genomic Research at www.tigr.org); Fm- DPP, DPP from Flavobacterium meningosepticum; Hs-DPP, human DPP FV; and Mm-FAP, mouse fibroblast activation protein.
- Peptide sequences obtained from PTP-A analysis described herein are indicated with arrows (note that the sequence of the peptide 81 -97 corresponds to the N-terminus of the lower molecular weight form of PTP-A); catalytic triad is marked with asterisks; and the proposed PTP-A membrane-anchoring N-terminal ⁇ -helix is double- underlined. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background.
- Fig. 4 Comparison of P. gingivalis PTP-A and DPP active site domains to corresponding sequences of three putative homologues identified within the P. gingivalis genome (DPP-HI, DPP-H2 and DPP-H3). Sequences of P. gingivalis PTP-A, DPP, DPP-HI , DPP-H2, and DPP-H3 were obtained from conceptual translation of the following open reading frames retrieved from The Institute for Genomic Research (TIGR) unfinished P. gingivalis genome database: gnl I TIGR I P.
- TIGR The Institute for Genomic Research
- gingivalis contig 126 (positions 13 228 - 15 426), contig 87 (positions 6424 - 4 399), contig 65 (positions 161 - 1 786), contig 101 (positions 8 895 - 6 845), and contig 9 (positions 4 216 - 2 162), respectively.
- Residues predicted as catalytic triads are marked with asterisks.
- Homologous regions i.e., regions of identical amino acids and/or conservative substitutions
- Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.
- Fig. 5 Influence of Pefabloc-serine proteinase inhibitor on P. gingivalis growth.
- Fig. 6 Comparison of P. gingivalis PTP-A and DPP to sequences of three putative homologues identified within the P. gingivalis genome (DPP-Hl, DPP-H2 and DPP-H3). Sequences of P. gingivalis PTP-A (126PP), DPP (87PP), DPP-Hl (65PP), DPP-H2 (101PP), and DPP-H3 (9PP) were obtained as described in Fig. 4. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.
- Fig. 7 Nucleotide sequence (SEQ ID NO:38) and amino acid sequence (SEQ H) NO:30) of PTP-A.
- the present invention provides isolated polypeptides, preferably isolated prolyl peptidases, more preferably prolyl dipeptidyl-peptidases and prolyl tripeptidyl-peptidases, most preferably prolyl-tripeptidyl peptidases, that have amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide, where the bond is between a proline and an amino acid residue attached to the alpha-carboxyl group end of the proline.
- the prolyl peptidase is a prolyl tripeptidyl-peptidase
- the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula NH 2 -Xaa-Xaa-Pro-Yaa-(Xaa) n (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or modified amino acid except proline, and the ⁇ -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Pro- Yaa peptide bond.
- isolated polypeptides do not cleave a target peptide having a blocked ⁇ -amino of the amino terminal residue.
- the only peptide bond of the target peptide that is hydrolyzed is the Pro- Yaa bond.
- isolated polypeptides can cleave a target peptide that is at least 4 amino acids or at least 300 Da, at least 10 a ino acids or at least 750 Da, at least 20 amino acids or at least 1,500 Da, or at least 30 amino acids or at least 3,000 Da.
- the prolyl-tripeptidyl peptidases cleave peptides 1, 2, 7, 8, and 10-15 shown in Table 3, human cystatin C, and interleukin 6.
- the prolyl peptidase is a prolyl dipeptidyl-peptidase
- the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula NH 2 -Xaa-Zaa-Yaa-(Xaa) n (SEQ LD NO: 12), wherein Xaa is a natural or modified amino acid, Zaa is a proline or alanine, Yaa is a natural or modified amino acid except proline or hydroxyproline, and the ⁇ -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Zaa- Yaa peptide bond.
- isolated polypeptides does not cleave a target peptide having a blocked ⁇ -amino of the amino terminal residue.
- the only peptide bond of the target peptide that is hydrolyzed is the Pro- Yaa bond.
- proline residues Due to their cyclic aliphatic character proline residues bestow unique conformational constraints on polypeptide chain structures, significantly affecting the susceptibility of proximal peptide bonds to proteolytic cleavage. Those proline residues, which often appear near the ammo-termini of many biologically active peptides, may protect them against proteolytic degradation by peptidases with general specificity.
- a specialized group of proteolytic enzymes typically referred to as prolyl peptidases, has evolved to cleave (i.e., hydrolyze) a peptide bond adjacent to a proline residue in a polypeptide.
- the peptide bond adjacent to a proline residue can be referred to as a prolyl-X bond, where prolyl is the proline residue, and X is an amino acid residue attached to the alpha-carboxyl group end of the proline.
- the bacterial prolyl peptidases can cleave a polypeptide to liberate a tripeptide or a dipeptide.
- Prolyl peptidases that do not cleave a target peptide if the ⁇ -amino of the amino terminal residue is blocked can be referred to as exopeptidases.
- proteolytic enzymes may have important physiological significance, because it may lead to inactivation of many biologically active peptides and/or transformation of the activity of other biologically active peptides.
- hydrolysis of prolyl-X bonds in conjunction with general catabolic pathways should allow the complete re- utilization of amino acids by living orgamsms, including bacteria.
- prolyl peptidases from bacterial pathogens if released into the host environment, may interfere with the physiological functions of biologically active polypeptides and, therefore, contribute to the pathogenicity of infectious disease.
- bacterial prolyl peptidases e.g., prolyl tripeptidyl peptidases and DPP IV
- bacterial prolyl peptidases e.g., prolyl tripeptidyl peptidases and DPP IV
- type I collagen is the major component of periodontal ligament, its enhanced degradation by bacterial prolyl peptidases may contribute to loss of tooth attachment and periodontal pocket formation.
- the polypeptides of the present invention can be used as a source of antibodies for inhibiting the peptidase activity and thereby possibly reducing periodontitis, loss of tooth attachment and periodontal pocket formation.
- Antibodies to prolyl peptidases can also be used to identify and/or isolate additional prolyl peptidases.
- Knowledge of prolyl peptidases can also be used to make inhibitors of prolyl peptidases and to make immunogenic compositions that could be used to elicit the production of antibodies to prolyl peptidases and thereby possibly reduce gingivitis, periodontitis, loss of tooth attachment, and/or periodontal pocket formation.
- prolyl-tripeptidyl peptidase A SEQ ID NO:30
- PTP-A prolyl-tripeptidyl peptidase A
- Purified PTP-A has apparent molecular masses of 81.8 and 75.8 kDa. The lower molecular mass peptidase may be due to the proteolytic cleavage of the peptidase from the surface of P. gingivalis.
- PTP-A is a new member of clan SC, family S9 of serine peptidases.
- Clans of serine peptidases are grouped on the basis of the order of certain amino acids in the polypeptide that make up the "catalytic triad" which plays a pivotal role peptidase activity.
- the members of the clan SC are characterized by the catalytic triad in the polypeptide in the order of serine, aspartic acid, and histidine.
- Members of the clan SC are also characterized by a tertiary structure including ⁇ / ⁇ / ⁇ units, and an ⁇ / ⁇ hydrolase fold.
- the amino acid sequence GXSXXG (SEQ LD NO:39), where X is any amino acid and S is the active site serine, is a signature of all members of the clan SC with some distinguishing features specific for each family.
- Family S9 has the consensus sequence GXSXGG (SEQ ID NO:40). Besides this consensus sequence, there is a general similarity of primary structures which classifies peptidases to this family. For instance, peptidases of this family generally have two domains, an ammo-terminal domain that contains a membrane binding domain, and a carboxy-terminal domain, also referred to as the catalytic domain. The catalytic domain contains the residues of the catalytic triad.
- S9A cytosolic oligopeptidases from archae and eukaryotes
- S9B eukaryotic acylaminoacylpeptidases
- S9C dipeptidyl peptidease IV from bacteria and eukaryotes.
- the catalytic domain of peptidases from family S9 typically begin at about residue 400 of SEQ DD NO:30 and include the remaining carboxy-terminal amino acids (see, e.g., Fulop, et al., (1998) Cell 94, 161-170).
- prolyl tripeptidyl peptidases with an activity that is increased by iodoacetamide relative to the same prolyl tripeptidyl peptidase in the absence of iodoacetamide under the same conditions.
- Iodoacetamide is a compound that is traditionally a peptidase inhibitor.
- the activity of a prolyl tripeptidyl peptidase is increased about two-fold.
- the prolyl tripeptidyl-peptidases of the present invention can cleave target peptidases having as few as 4 amino acids but also target peptides having at least 30 amino acids or a molecular weight of at least 3,000 Da.
- the P. gingivalis tripeptidyl peptidase is a unique enzyme, and the isolation and characterization of this novel bacterial prolyl peptidase will facilitate the development of therapies to inhibit the activity of the bacterial peptidases.
- Examples of putative prolyl-dipeptidyl peptidases are DPP-Hl (SEQ ID NO: 1
- DPP-H2 (SEQ LD NO:44), and DPP-H3 (SEQ LD NO:45).
- These peptidases have a significant percentage amino acid similarity with DPP IV and PTP-A (see Fig. 6).
- Each dipeptidyl peptidase is expected to have enzymatic activity, as each has a well preserved catalytic triad (Fig. 4).
- DPP IV has been characterized and the gene encoding the peptidase has been cloned, however the substrate specificity has not been well characterized.
- DPP IV has been found to cleave SEQ ID NOs:6, 20, 23, and 24.
- DPP IV has been purified in two forms.
- One of the forms is a full length gene translation product containing a blocked ammo-terminal residue.
- the second form had the ammo-terminal amino acid sequence HS YRAAVYDYDVRRNLVKPLSEHVG (SEQ LD NO:48), which corresponds to residues 116-140 of DPP IV (Kiyama, M., et al. (1998) 1396, 39- 46), indicating that it was proteolytically truncated on the ammo-terminus.
- PTP-A and DPP IV activity is cell surface associated. While not intending to be limiting, it is conceivable that the enzyme is membrane anchored through a putative signal sequence which is not cleaved but remains as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. However, a significant portion of the purified PTP-A has a truncated N- terminus, apparently due to cleavage by Lys-specific peptidase and likely to be an artifact which has occurred during the purification procedure.
- membrane bound PTP-A and DPP IV is proteolytically cleaved and shed during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media.
- the cell surface localization of PTP-A supports a putative physiological function in providing nutrients for growing bacterial cells.
- the inability of asaccharolytic P. gingivalis to utilize free amino acids makes the bacterium entirely dependant on an external peptide supply.
- PTP-A and DPP IV activities are probably very important, if not indispensable, for bacterial growth, and inhibition of prolyl tripeptidyl-peptidases and dipeptidyl- peptidases may inhibit the in vivo growth of organisms, including P. gingivalis. For instance, treatment of P.
- a polypeptide of the invention preferably a prolyl peptidase, contains the amino acid sequence GXSXXG (SEQ ID NO:39), most preferably, GXSXGG (SEQ LD NO:40), where G is glycine, X is any amino acid, and S is the active site serine.
- the active site serine can be identified by, for instance, labeling with diisopropylfiuorophosphate as described herein.
- the catalytic domain of the prolyl tripeptidyl-peptidases of the invention begins at about residue
- SEQ ID NO:30 400 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6), more preferably, at about residue 502 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6), most preferably, at about residue 556 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6).
- the invention further includes a polypeptide, preferably a prolyl tripeptidyl- peptidase, that shares a significant level of primary structure with SEQ ID NO:30.
- the two amino acid sequences i.e., the amino acid sequence of the polypeptide and the sequence SEQ ID NO: 30
- the two amino acid sequences are aligned such that the residues that make up the catalytic triad, i.e., the serine, aspartic acid, and the histidine, are in register, then further aligned to maximize the number of amino acids that they have in common along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to place the residues of the catalytic triad in register and to maximize the number of shared amino acids, although the amino acids in each sequence must nonetheless remain in their proper order.
- the percentage amino acid identity is the higher of the following two numbers: (a) the number of amino acids that the two sequences have in common within the alignment, divided by the number of amino acids
- a prolyl tripeptidyl peptidase has greater than 35 % identity, more preferably at least about 40 % identity, most preferably at least about 45 % identity with SEQ ID NO:30.
- amino acids 154-732 of SEQ ID NO:30 are used, more preferably amino acids 400-732 of SEQ DD NO:30 are used.
- An isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ
- the amidolytic activity of the polypeptides of the invention can be measured by assay of the cleavage of a target polypeptide in the presence of prolyl peptidase and a buffer.
- the lower ratio of prolyl tripeptidyl-peptidase to target polypeptide is at least about 1:1, more preferably at least about 1 : 100, even more preferably at least about 1 : 1 ,000, most preferably at least about 1 : 10,000.
- the higher ratio of prolyl peptidase to target polypeptide is no greater than about 1:10,000,000, more preferably no greater than about 1 : 1,000,000 and most preferably no greater than about 1:100,000. Buffers in which a prolyl peptidase is active are suitable for the assay.
- the buffer is about 200 mM HEPES (N-2-hydroxyethylpeperazine,N'-2- ethansulfonic acid), more preferably about 50 mM HEPES, most preferably about 20 mM HEPES.
- the pH of the buffer is at least about pH 6.0 and no greater than pH 8.0, more preferably about pH 7.5.
- the temperature of the assay is at about 37°C. The assay can be carried out for at least about 1 minute to no greater than 24 hours.
- the amidolytic activity of the prolyl peptidases are measured at a prolyl peptidase:target polypeptide ratio of at least about 1 : 100 to no greater than 1 : 1,000,000 in about 200 mM HEPES, about pH 7.5 at about 37°C for at least about 3 hours.
- the time of the assay can vary depending on the substrate and enzyme:substrate ratio.
- target peptides are stable under these conditions, and typically it is difficult to detect background levels of hydrolysis in the absence of a prolyl peptidase.
- the assay is allowed to continue until at least 1 % of the target peptide is hydrolyzed.
- Prolyl-tripeptidyl peptidases of the present invention preferably are inhibited by a compound chosen from the group consisting of PEFABLOCK (4-(2- aminoethyl)-benzenesulfonyl-fluoride hydrochloride), diisopropylfiuorophosphate, and 3,4-dichloroisocoumarin, more preferably PEFABLOCK and diisopropylfiuorophosphate, and most preferably diisopropylfiuorophosphate.
- PEFABLOCK 4-(2- aminoethyl)-benzenesulfonyl-fluoride hydrochloride
- diisopropylfiuorophosphate 2,3-dichloroisocoumarin
- the peptidases of the present invention are preferably not inhibited by a compound chosen from the group consisting of leupeptin, antipain, E-64, pepstatin, ⁇ proteinase inhibitor, ⁇ j -antichymotrypsin and ⁇ 2-macroglobulin, most preferably.
- a compound chosen from the group consisting of leupeptin, antipain, E-64, pepstatin, ⁇ proteinase inhibitor, ⁇ j -antichymotrypsin and ⁇ 2-macroglobulin most preferably.
- the amidolytic activity of a prolyl-tripeptidyl peptidase of the present invention is increased by iodoacetamide relative to the prolyl-tripeptidyl peptidase in the absence of iodoacetamide under the same conditions.
- the effect of iodoacetamide on amidolytic activity is measured by incubating in 200 mM HEPES, pH 7.6, at least about 0.1 nM of the prolyl tripeptidyl-peptidase with the inhibitor for about 15 minutes, adding about 1 mM of H-Ala-Phe-Pro-pHA, and incubating for at least about 1 minute before assaying for amidolytic activity. Typically, at least about 1 mM to no greater than 100 mM of inhibitor is used.
- the polypeptides of the invention include a polypeptide having SEQ ID NO:30, or an active analog, active fragment, or active modification of SEQ ID NO:30.
- An active analog, active fragment, or active modification of a polypeptide having SEQ ID NO:30 is one that has amidolytic activity by hydrolysis of the Pro- Yaa peptide bond present in a target polypeptide of the general formula NH 2 -Xaa- Xaa-Pro-Yaa-(Xaa) n (SEQ ID NO:25).
- Active analogs of a polypeptide having SEQ ID NO:30 include prolyl-tripeptidyl peptidases having amino acid substitutions that do not eliminate hydrolysis of SEQ ID NO:25 at the Pro- Yaa peptide bond.
- Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs.
- nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine.
- Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged
- (basic) amino acids include arginine, lysine and histidine.
- the negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of preferred conservative substitutions include Lys for Arg and vice versa to maintain a positive charge; Glu for Asp and vice versa to maintain a negative charge; Ser for Thr so that a free -OH is maintained; and Gin for Asn to maintain a free NH 2 .
- Active fragments of a prolyl-tripeptidyl peptidase of the invention include prolyl-tripeptidyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will hydrolyze SEQ ID NO:25 at the Pro- Yaa peptide bond.
- An example of a fragment of a prolyl-tripeptidyl peptidase is a catalytic domain.
- Modified prolyl-tripeptidyl peptidases include prolyl-tripeptidyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like. Modified prolyl-tripeptidyl peptidases will hydrolyze SEQ ID NO:25 at the Pro- Yaa peptide bond. Prolyl peptidases can be obtained by several methods.
- Isolation of a prolyl- tripeptidyl peptidase present on the surface of a cell producing the peptidase typically requires lysis of the cell followed by purification methods that are well known in the art.
- eels can be treated with a detergent, for instance Triton X-100, to remove the peptidase from the cell surface.
- Suitable protein purification procedures fractionation on immunoaffinity, ion-exchange, hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5, or MonoP columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an ion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75.
- isolation of a prolyl-tripeptidyl peptidase from P. gingivalis is accomplished using a combination of hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5 and MonoP column chromatography steps as described herein.
- Prolyl peptidases can also be isolated from organisms other than P. gingivalis. Other organisms can express a prolyl-tripeptidyl peptidase that is encoded by a coding region having similarity to the PTP-A coding region.
- a "coding region” is a linear form of nucleotides that encodes a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of a coding region are generally determined by a translation start codon at its 5' end and a translation stop codon at its 3' end.
- "Regulatory region” refers to a nucleic acid fragment that regulates expression of a coding region to which a regulatory region is operably linked.
- Non limiting examples of regulatory regions include promoters, transcription initiation sites, translation start sites, translation stop sites, and terminators.
- "Operably linked” refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
- a regulatory element is "operably linked" to a coding region when it is joined in such a way that expression of the coding region is achieved under conditions compatible with the regulatory region.
- other organisms can express a prolyl-tripeptidyl peptidase from a recombinant coding region encoding the peptidase. The identification of similar coding regions in other organisms can be accomplished as described herein.
- a prolyl-tripeptidyl peptidase can be isolated using purification methods that are well known in the art.
- the peptidase can be chemically synthesized using methods that are well known in the art including, for instance, solid phase synthesis. Examples of, for instance, coding and regulatory regions are described herein.
- a prolyl-tripeptidyl peptidase by an organism other than P. gingivalis can be detected using specific substrates of the general formula NH 2 - Xaa-Xaa-Pro-LG or NH 2 -Xaa-Xaa-Pro-Yaa (SEQ ID NO:41), where LG is a leaving group.
- the leaving group can be a chromogenic or fluorogenic group known to the art.
- the expression of a prolyl-tripeptidyl peptidase by an organism and subsequent cleavage of a specific substrate results in a free amino acid or a free leaving group, each of which can be assayed using techniques known to those of skill in the art. Other methods can be based on immunogenic properties of PTP-A, for instance immunoassays and histochemistry, the detection of mRNA, and PCR related methods, all of which are known to one of skill in the art.
- the amino acid sequence of the amino- terminal end of a PTP-A fragment was used to identify the nucleotide sequence of the PTP coding region.
- the nucleotide sequence was present in a publically available database containing the nucleotide sequence of the partially finished P. gingivalis W83 genome.
- the nucleotides that encode the P. gingivalis PTP-A were known, there was no indication that the nucleotides were in fact transcribed and translated.
- the data obtained from the database only contained the nucleotide sequence of a genomic clone; there was no disclosure that the nucleotides did or did not contain an open reading frame.
- nucleic acid fragment encoding a polypeptide, particularly a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof.
- the nucleic acid fragment can have a nucleotide sequence as shown in SEQ ID NO: 38.
- nucleic acid fragments of the invention include those whose complement hybridize to SEQ LD NO:38 under standard hybridization conditions as described herein. During hybridization the entire nucleotide sequence of the complement can hybridize with SEQ ID NO:38.
- at least about 20 nucleotides of the complement hybridize with SEQ LD NO:38, more preferably at least about 50 nucleotides, most preferably at least about 100 nucleotides.
- the nucleic acid fragment can have a nucleotide sequence encoding a polypeptide having the amino acid sequence shown in SEQ DD NO:30.
- An example of the class of nucleotide sequences encoding such a polypeptide is SEQ ID NO:38. This class of nucleotide sequences is large but finite, and the nucleotide sequence of each member of the class can be readily determined by one skilled in the art by reference to the standard genetic code.
- the identification of similar coding regions in other organisms can be accomplished by screening individual wild-type microorganisms for the presence of nucleotide sequences that are similar to the coding region of PTP-A, which is shown in SEQ ID NO:38. Screening methods include, for instance, hybridization of a detectably labeled probe with a nucleic acid fragment.
- Standard hybridizing conditions are a modification of the conditions used by Church et al. ((1984) Proc. Natl. Acad. Sci. USA 81, 1991): 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, and three washes, each for 20 minutes in 2x SSC, 0.1 % SDS, at 65°C.
- a probe will hybridize to the nucleotide sequence set forth in SEQ ID NO:38 under standard hybridizing conditions. Generally the probe does not have to be complementary to all the nucleotides of the nucleic acid fragment as long as there is hybridization under the above-stated conditions.
- “Complement” and “complementary” refer to the ability of two single stranded nucleic acid fragments to base pair with each other, where an adenine on one nucleic acid fragment will base pair to a thymine on a second nucleic acid fragment and a cytosine on one nucleic acid fragment will base pair to a guanine on a second nucleic acid fragment.
- Two nucleic acid fragments are complementary to each other when a nucleotide sequence in one nucleic acid fragment can base pair with a nucleotide sequence in a second nucleic acid fragment. For instance, 5'- ATGC and 5 '-GC AT are complementary.
- complement and complementary also encompasses two nucleic acid fragments where one nucleic acid fragment contains at least one nucleotide that will not base pair to at least one nucleotide present on a second nucleic acid fragment.
- the third nucleotide of each of the two nucleic acid fragments 5'-ATTGC and 5'-GCTAT will not base pair, but these two nucleic acid fragments are complementary as defined herein.
- two nucleic acid fragments are complementary if they hybridize under the standard conditions referred to herein.
- Preferred probes are nucleic acid fragments complementary to a coding region or another nucleotide sequence that encodes a prolyl-tripeptidyl peptidase.
- a probe can comprise a consecutive series of nucleotides complementary to a portion of SEQ ID NO:38.
- a probe is at least about 18 bases, more preferably at least about 21 bases, and most preferably at least about 24 bases in length.
- Particularly preferred probes are TTCGATCCGGCAAAGAAATATCCTGTTATTGTCTATGTTTACGGAGGAC CT (SEQ ID NO:36,
- the nucleic acid fragment that is identified by the probe is further analyzed to determine if it encodes a polypeptide with amidolytic activity of the Pro- Yaa peptide bond on a target polypeptide of the general formula NH 2 -Xaa-Xaa-Pro- Yaa-(Xaa) n (SEQ ID NO:25).
- Another method for screening individual microorganisms for the presence of nucleotide sequences that are similar to the coding regions of the present invention is the polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- Individual wild-type microorganisms containing nucleic acid fragments encoding a prolyl-tripeptidyl peptidase can also be identified using antibody.
- the antibody is directed to PTP-A.
- the production of antibodies to a particular polypeptide is known to a person of skill in the art, and is further detailed herein.
- the use of hybridization of a probe to a coding region present in individual wild-type microorganisms can be used as a method to identify a coding region identical or similar to a coding region present in SEQ LD NO:38.
- the coding region can then be isolated and ligated into a vector as described below.
- Two nucleic acid sequences are "similar” if the two nucleic acid sequences can be aligned so that the number of identical amino acids along the lengths of their sequences are optimized.
- two nucleotide acid sequences have, in increasing order of preference, preferably at least about 90 %, at least about 92 %, at least about 94%, at least about 96%, most preferably at least about 98% identity.
- a nucleic acid fragment of the invention can be inserted in a vector.
- Construction of vectors containing a nucleic acid fragment of the invention employs standard ligation techniques known in the art. See, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989) or Ausubel, R.M., ed. Current Protocols in Molecular Biology (1994).
- a vector can provide for further cloning (amplification of the nucleic acid fragment), i.e., a cloning vector, or for expression of the polypeptide encoded by the coding region, i.e., an expression vector.
- vector includes, but is not limited to, plasmid vectors, viral vectors, cosmid vectors, or artificial chromosome vectors.
- a vector is capable of replication in a bacterial host, for instance E. coli.
- the vector is a plasmid. Selection of a vector depends upon a variety of desired characteristics in the resulting construct, such as a selection marker, vector replication rate, and the like.
- Suitable plasmids for expression in E. coli for example, include pUC(X), pKK223- 3, pKK233-2, pTrc99A, and pET-(X) wherein (X) denotes a vector family in which numerous constructs are available.
- pUC(X) vectors can be obtained from Pharmacia Biotech (Piscataway, NH) or Sigma Chemical Co. (St. Louis, MO).
- pKK223-3, pKK233-2 and pTrc99A can be obtained from Pharmacia Biotech.
- pET-(X) vectors can be obtained from Promega (Madison, Wt) Stratagene (La Jolla, CA) and Novagen (Madison, WI).
- the vector preferably includes an origin of replication (known as an "ori") or replicon.
- an origin of replication known as an "ori”
- ColEl and PI 5 A replicons are commonly used in plasmids that are to be propagated in E. coli.
- An expression vector optionally includes regulatory regions operably linked to the coding region.
- the invention is not limited by the use of any particular promoter, and a wide variety are known. Promoters act as regulatory signals that bind RNA polymerase in a cell to initiate transcription of a downstream (3' direction) coding region.
- the promoter used in the invention can be a constitutive or an inducible promoter. It can be, but need not be, heterologous with respect to the host cell.
- Preferred promoters for bacterial transformation include lac, lac ⁇ JV5, tac, trc, T7, SP6 and ara.
- An expression vector can optionally include a Shine Dalgarno site (e.g., a ribosome binding site), and a start site (e.g., the codon ATG) to initiate translation of the transcribed message to produce the enzyme. It can also include a termination sequence to end translation. A termination sequence is typically a codon for which there exists no corresponding aminoacetyl-tRNA, thus ending polypeptide synthesis.
- the nucleic acid fragment used to transform the host cell can optionally further include a transcription termination sequence.
- the rrnB terminators which is a stretch of DNA that contains two terminators, Tl and T2, is an often used terminator that is incorporated into bacterial expression systems (J. Brosius et al.,
- the nucleic acid fragment used to transform the host cell optionally includes one or more marker sequences, which typically encode a polypeptide that inactivates or otherwise detects or is detected by a compound in the growth medium.
- a marker sequence can render the transformed cell resistant to an antibiotic, or it can confer compound-specific metabolism on the transformed cell.
- Examples of a marker sequence are sequences that confer resistance to kanamycin, ampicillin, chlorarnphenicol, and tetracycline.
- Antibodies can be produced to a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45, or a polypeptide having a percentage amino acid identity as described herein.
- antibodies can be made to an antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45.
- An antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 is one that generates an immune response in an animal.
- Antigenic analogs of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 include prolyl peptidases having amino acid substitutions that do not eliminate peptide antigenicity in an animal. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs, as described herein.
- Fragments of a prolyl peptidase of the invention include prolyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will generate an immune response in an animal.
- An example of a fragments of a prolylpeptidase is a catalytic domain.
- Modified prolyl peptidases include prolyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acids, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.
- an aspect of the invention is an immunogenic composition
- the prolyl tripeptidyl-peptidase preferably has amidolytic activity for cleavage of the Pro- Yaa peptide bond present in a target polypeptide with the general formula NH 2 -
- the immunogenic composition can further include excipients or diluents that are pharmaceutically acceptable as carriers and compatible with the immunogenic composition.
- pharmaceutically acceptable carrier refers to a carrier(s) that is "acceptable” in the sense of being compatible with the other ingredients of a composition and not deleterious to the recipient thereof.
- Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof.
- the immunogenic composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and or adjuvants which enhance the effectiveness of the immune-stimulating composition.
- the immunogenic composition can be used in a method for protecting an animal from a disease caused by P. gingivalis.
- This method includes administering the immunogenic composition and eliciting antibodies to a prolyl peptidase, antigenic analog, antigenic fragment, or antigenic modification.
- the diseases that can be treated in this manner include periodontal diseases, which includes gingivitis and periodontitis. Clinical hallmarks of periodontitis include lose of tooth attachment and periodontal pocket formation.
- periodontal diseases can be treated by the use of inhibitors of a prolyl peptidase.
- An inhibitor of a prolyl peptidase preferably a prolyl tripeptidyl-peptidase, can be present in a composition that preferably contains a pharmaceutically acceptable carrier.
- inhibitors can be applied systemically, subgingivally (e.g., subgingival irrigation) and/or by controlled release delivery directly into the periodontal pocket using methods well known to the art (see, e.g., Kornman, K., (1993) J Periodontol. 64, 782-791).
- an inhibitor is applied subgingivally or by controlled release delivery.
- the prolyl peptidases, active analogs, fragments, and modifications thereof can be used in a method of reducing growth of bacteria in vitro or in vivo.
- the bacteria is a periodontal pathogen, i.e, a bacterial pathogen that causes periodontal disease, more preferably the bacteria is P. gingivalis.
- P. gingivalis a periodontal pathogen that causes periodontal disease
- the action of the polypeptides of the invention may be required for bacterial growth, and inhibition of the polypeptides of the invention may inhibit the in vivo growth of organisms, including P. gingivalis.
- the method includes decreasing the amount of dipeptides and/or tripeptides (e.g., the result of cleavage of SEQ ID NO:25 by a prolyl- tripeptidyl peptidase) and the amount of free amino acids that result from further cleavage of the dipeptides and/or tripeptides present by inhibiting a prolyl peptidase, active analog, active fragment, or active modification thereof, such that the amount of dipeptides and/or tripeptides generated by the polypeptides is decreased.
- the amount of dipeptides and/or tripeptides is decreased relative to the amount of dipeptides and/or tripeptides present in the absence of the inhibitor.
- the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor, a monoclonal antibody that inhibits the prolyl peptidase, or polyclonal antibodies that inhibit the prolyl peptidase, more preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor.
- an inhibitor acts to inhibit a polypeptide of the invention, preferably a prolyl peptidase, by blocking the active site of the polypeptide.
- the polypeptide can be present on the surface of the bacteria or secreted into the environment, preferably the polypeptide is present in the surface of the bacteria.
- the present invention is also directed to a method of developing an inhibitor of a prolyl peptidase, active analog, active fragment, or active modification thereof, preferably a prolyl-tripeptidyl peptidase.
- the method includes identifying a molecule that inhibits the amidolytic activity of the prolyl peptidase. This can be accomplished by, for instance, incubating the prolyl peptidase with a candidate molecule under conditions that promote amidolytic activity of the prolyl peptidase and determining if the amidolytic activity of the prolyl peptidase is decreased relative to the amidolytic activity in the absence of the molecule.
- the amidolytic activity can be measured by cleavage of the Pro- Yaa peptide bond present in the target polypeptide SEQ ID NO:25 as described herein.
- One method of developing an inhibitor includes using the target peptide SEQ ID NO:25 and replacing the Xaa residues with modified amino acids. It is expected that some modified amino acids will cause the target peptide to act as an inhibitor.
- DFP Diisopropylfiuorophosphate
- leupeptin 3,5,4-dichloroisocoumarin
- Calbiochem Calbiochem (La Jolla, CA).
- H-Ala-Phe- Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, and H-Pro-pNA (where pNA is p- Nitroanilide; Z is benzyloxycarbonyl; and H is hydrogen and denotes an unblocked ammo-teiminal group) were obtained from Bachem (King of Prussia, PA).
- Prolinal was kindly provided by Dr. James Powers (Georgia Institute of Technology, Atlanta) and cystatin C by Dr. Magnus Abrahamson (University of Lund, Sweden).
- Enzyme Activity Assays Routinely, the tripeptidyl peptidase amidolytic activity was measured with H-Ala-Phe-Pro-pNA (lmM) in 0.2 M HEPES (N-2- hy(iroxyethylpeperazine,N'-2-ethansulfonic acid), pH 7.5 at 37°C. The concentration of enzyme was 0.1 nM to 1 nM. The assay was performed in a total volume of 0.2 ml on microplates, and the initial turnover rate was recorded at 405 nm using a microplate reader (Spectramax Molecular Devices, Sunnyvale, CA).
- H-Gly-Pro-pNA, Z-Ala-Pro-pNA, Z-Gly-Pro-pNA and H-Pro-pNA (1 mM final concentration) were assayed in the same manner.
- Protein Determination Protein concentration was determined using the BCA reagent kit (Sigma, St. Louis, MO), using bovine serum albumin as a standard.
- Tripeptidyl-Peptidase Activity Cultures of P. gingivalis HG66, W50 and ATCC 33277, at different phases of growth, were subjected to the following fractionation procedure. The cells were removed by centrifugation (10,000 x g, 30 minutes), washed twice with 10 mM Tris, 150 mM NaCl, pH 7.4, resuspended in 50 mM Tris, pH 7.6, and disintegrated by ultrasonication in an ice bath at 1500 Hz for 5 cycles (5 minutes sonication/5 minutes brake).
- Enzyme Purification All purification steps were performed at 4°C except for FPLC separations, which were carried out at room temperature. Cells were harvested by centrifugation (6,000 x g, 30 minutes), washed with 50 mM potassium phosphate buffer, pH 7.4, and resuspended in the same buffer (150 ml per 50 gram of cells wet weight). Triton X- 100 (10% volume/volume in H 2 O) was added slowly to the bacterial cell suspension to a final concentration of 0.05%. After 120 minutes of gentle stirring, unbroken cells were removed by centrifugation (28,000 x g, 60 minutes).
- Proteins in the supernatant were precipitated with cold acetone (- 20°C) added to a final concentration of 60% and collected by centrifugation.
- the pellet was redissolved in 50 mM potassium phosphate buffer, pH 7.0, and extensively dialyzed against 20 mM potassium phosphate, pH 7.0, containing 0.02% sodium azide.
- the dialyzed fraction was clarified by centrifugation (28,000 x g, 30 min) and applied to a hydroxyapatite column (BioRad, Melville, NY) equilibrated with 20 mM potassium phosphate, pH 7.0, at a flow rate of 20 ml hour. After equilibration, the column was washed until the A 280 fell to zero.
- Bound proteins were eluted with a gradient from 20-300 mM potassium phosphate and fractions (7 ml) analyzed for dipeptidyl- and tripeptidyl-peptidase activity using H- Gly-Pro-pNA and H-Ala-Phe-Pro-pNA, respectively.
- the activity against the latter substrate was pooled, saturated with 1 M ammonium sulfate, clarified by centrifugation, and directly loaded onto a Phenyl-Sepharose HP (Pharmacia, Piscataway, NJ) column equilibrated with 50 mM potassium phosphate, pH 7.0, containing 1 M ammonium sulfate.
- the column was washed with two volumes of equilibration buffer, followed by buffer containing 0.5 M ammonium sulfate, and developed with a descending gradient of ammonium sulfate from 0.5 to 0 M. Active fractions were pooled, extensively dialyzed against 20 mM Tris, pH 7.5, and applied to a MonoQ HR 5/5 FPLC column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer at 1.0 ml minute, following which bound proteins were eluted with a gradient of 0- 300 mM NaCl.
- the active fractions were pooled, dialyzed against 25 mM Bis-Tris, pH 6.3, and subjected to chromatofocusing on a MonoP FPLC column equilibrated with Bis- Tris buffer, using a pH gradient developed with 50 ml of 1 Ox diluted Polybuffer 74 (Pharmacia), adjusted to a pH of 4.0. Electrophoretic Techniques — The SDS-PAGE system of Schagger and von
- the blot was air dried, and protein bands cut out and subjected to NH 2 - terminal sequence analysis with an Applied Biosystems 491 Protein Sequencer using the program designed by the manufacturers.
- Enzyme Fragmentation The purified prolyl tripeptidyl peptidase (PTP-A) was partially denatured by incubation in 6 M urea in 0.02 M Tris, pH 7.6, for 60 minutes.
- Low molecular mass gingipain R (RgpB) (Potempa, J., et al. (1995) Prospect. Drug Discovery and Design 2, 445-458) from P. gingivalis was then added to make an enzyme:substrate molar ratio of 1 : 100.
- the reaction mixture was made in 1 mM cysteine and the sample incubated overnight at 37°C. Generated peptides were separated by reverse-phase HPLC using a ⁇ Bondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA). Peptides were eluted with 0.1% trifluoroacetic acid and acetonitrile containing 0.08% trifluoroacetic acid, using a gradient from 0 to 80% acetonitrile over 60 minutes. Peptides were monitored at 220 nm and collected manually.
- radiolabelled protein was subjected to proteolytic fragmentation with RgpB and peptides obtained separated by reverse- phase HPLC as described above. Radioactivity in each peptide fraction was measured using a ⁇ liquid scintillation counter, and the labeled peptide, as well as other selected peptides were subjected to sequence analysis.
- Enzyme Specificity Peptides were incubated with 1 ⁇ g PTP-A at an enzyme:substrate molar ratio of 1 : 100 for 3 hours or 24 hours in 50 ⁇ l of 200 mM
- Mass Spectrometry A Finnigan MAT 95 S, sector mass spectrometer (Finnigan MAT, Bremen, Germany) equipped with an electrospray source (ESI) was used operated essentially as described previously (Stenfors, C, et al., (1997) J. Biol. Chem. 272. 5747-5751). Peptides were identified by fitting of the obtained spectra to specific sequences using an Internet application program MsFit available at http://falcon.ludwig.ucl.ac.uk/msfit.html.
- Example 2 Enzyme Localization, Purification and Initial Characterization Analysis of amidolytic activity against H-Ala-Phe-Pro-pNA in several fractions of P. gingivalis HG66, W50 and ATCC 33277 clearly indicated that an enzyme(s) with prolyl tripeptidyl-peptidase activity is localized on the cell surface in all strains tested with less than 5% of the total activity being found in the medium regardless of the growth phase of the bacterial culture. Cell associated enzyme was easily detached from the bacterial surface by treatment with a low concentration (0.05%) of Triton X-100. This procedure released more than 85-90% of activity in a soluble form.
- Phenyl-Sepharose HP (25 ml) was equilibrated with 50 mM potassium phosphate, 1M ammonium sulfate, pH 7.0, at flow rate 30 ml/h.
- the column was washed with two volumes of equilibration buffer and a step gradient of 0.5 M ammonium sulfate was applied, following which a descending gradient of 0.5 to 0 M ammonium sulfate was applied.
- the PTP-A containing fractions were extensively dialyzed against 20 mM Tris-HCl, pH 7.0, and concentrated by ultrafiltration. The concentrated PTP-A containing fractions were applied to a
- MonoQ column equilibrated with the same buffer was washed with 5 volumes of equilibration buffer, following which bound protein was eluted with a gradient of 0-300 mM NaCl.
- the concentrated fraction of PTP-A from the MonoQ column was equilibrated with 25 mM Bis-Tris, pH 6.3, and loaded on a MonoP column equilibrated with the same buffer.
- a pH gradient was developed using 50 ml of Polybuffer 74, with the pH adjusted to 4.0.
- Example 3 pH Optimum, Stability and Inhibition Profile Using the amidolytic activity assay with H-Ala-Phe-Pro-pNA it was found that the enzyme has a broad pH optimum from pH 6.0 to 8.0 and in 0.2 M HEPES, pH 7.6 was stable for at least 12 hours at 25°C or 37°C. PTP-A activity was not affected by class specific synthetic inhibitors of cysteine or metalloproteinases (Table 2). In contrast, preincubation of the enzyme with DFP or PEFABLOCK resulted in total loss of activity, supporting its classification as a serine peptidase.
- Pro-pNA as a substrate.
- Phenylmethanesulfonyl fluoride lmg/ml 20 15 lOmg/ml 0 0
- H-Ala-Phe-Pro- pNA H-Gly-Pro-pNA
- Z-Gly-Pro-pNA Z-Ala-Pro-pNA
- H-Pro-pNA only H-Ala- Phe-Pro-pNA was hydrolyzed by PTP-A indicating a prolyl specific tripeptidyl- peptidase activity.
- synthetic peptides composed of 5 to 34 amino acid residues and containing at least one proline residue were tested as substrates for PTP-A.
- Out of 22 peptides tested only those with a proline residue in the third position from the amino terminal end were cleaved (Table 3), with the significant exception of peptides with adjacent proline residues
- the peptide bond -Pro- ⁇ - Yaa- was cleaved at the same rate in all peptides with the general formula NH 2 -Xaa-Xaa-Pro-Yaa-(Xaa) n (SEQ ID NO:25), where Xaa represents any amino acid residue while Yaa could be any residue except proline, regardless of the chemical nature of the arnino acids and the length of the peptide.
- the reaction was completed within 3 hours and prolonged incubation for 24 hours did not affect the pattern of cleavage, confirming the absolute requirement for a proline residue at the third position from the unblocked N-terminus.
- Peptide 6 H-Arg-Pro- 1 -Lys-Pro- 1 -Gln-Gln-Phe-Phe-Gly-Leu-Met-NH 2 6
- Peptide 7 H-Val-Pro-Pro- I -Gly-Glu-Asp-Ser-Lys-Glu-Val-Ala-Ala-Pro-His-Arg-Gln 7
- Peptide 8 H-Val-Pro-Pro- 1 -Gly-Glu-Asp-Ser-Lys 8
- Peptide 12 H-Ala-Arg-Pro- 1 -Ala-D-Lys-amide Peptide 13 H-Pro-Asn-Pro- 1 -Asn-Gln-Gly-Asn-Phe-Ile 13
- Peptide 15 H-Gly-Val-Pro- 1 -Lys-Thr-His-Leu-Glu-Leu 15
- Peptide 20 H-Leu-Pro- 1 -Asp-Leu-Asp-Ser-Ser-Leu-Ala-Ser-Ile-Gln-Glu-Leu-Leu-Ser-Pro-Gln-Glu-Pro-Pro-Arg-Pro-Pro- 20
- Peptide 21 H-Cys-Leu-Ser-Ser-Gly-Thr-Leu-Pro-Gly-Pro-Gly-Asn-Asp-Ala-Ser-Arg-Glu-Leu-Glu-Ser 21
- Peptide 24 H-Ala-Pro-t -Val-Arg-Ser-Leu-Asn-Cys-Thr-Leu-Arg-Asp-Ser-Gln-Gln-Lys 47
- Partial PTP-A amino acid sequence data allowed us to identify the P. gingivalis genomic clone gnl
- An ORF corresponding to the PTP-A amino acid sequence was found as indicated by the fact that all sequences of the PTP-A derived peptides obtained by the enzyme polypeptide fragmentation with RgpB were present in the protein primary structure inferred from the nucleotide sequence of the ORF.
- the 732 amino acid polypeptide with a calculated mass of 82, 266 Da was encoded in this ORF.
- PTP-A was most closely related to bacterial dipeptidyl peptidase TV (DPP IV) from Flavobacterium meningosepticum, Xantomonas maltophilus, and P. gingivalis, sharing 31.6%, 30.4%, and 28.5% amino acid sequence identity, respectively.
- DPP IV dipeptidyl peptidase TV
- the COOH-terminal region of the PTP-A molecule shows a significant similarity to the eukaryotic prolyl oligopeptidases with 34% and 33% identity to human DPP IV and mouse fibroblast activation protein (FAP), respectively (Fig. 3).
- This part of the molecule contains the amino acid residues which encompass the catalytic triad in all characterized prolyl oligopeptidases, and from the multiple alignments with DPP IV of confirmed active site residues (Kabashima,T., et al., (1995) Arch. Biochem. Biophys. 320.
- Ser-603, Asp-678 and His-710 represent the catalytic triad of PTP- A (Fig. 3). Such an inference is further supported by the direct labeling of Ser-603 by DFP.
- the computer assisted search for sequential motifs characteristic for transmembrane domains revealed the presence of such a putative region within the N-terminal sequences of PTP-A, with residues 5 to 25 most likely folded into a hydrophobic ⁇ -helix responsible for membrane anchoring of this enzyme.
- P. gingivalis in logphase growth was diluted 1 :5 into hquid media and incubated at 37°C.
- the cell density was monitored by measuring the optical density at 600 nm (OD ⁇ ).
- OD ⁇ optical density
- Pefabloc was added at 0.5 mg/ml or at 2.0 mg/ml.
- the control culture received no Pefabloc.
- the cultures receiving Pefabloc exhibited decreased growth ( Figure 5).
- the peptidase inhibitor had to be added before the culture reached an OD ⁇ of about 0.3 for the peptidase inhibitor to have an effect on growth.
- SEQ ID Nos: 13-22 Synthetic peptides
- SEQ ID NO:23 Ammo-terminus of the lower molecular mass form of PTP-
- SEQ DD NO:24 Amino acid sequence present in PTP-A, where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP.
- SEQ ID NO:25 Target peptide, where Xaa represents a natural or modified amino acid residue, Yaa represents a natural or modified amino acid residue except proline, and N is equal to or greater than 1.
- SEQ ID NO:26 Mouse fibroblast activation protein
- SEQIDNO:27 Human DPP IV
- SEQIDNO:28 DPP from Flavobacterium meningosepticum
- SEQ ID NO:29 DPP from P. gingivalis
- SEQ ID NO:30 P.
- gingivalis PTP-A SEQIDNO:31 Portion of PTP-A SEQIDNO:32: Portion of DPP from P. gingivalis SEQIDNO:33: Portion of HI homolog of P. gingivalis DPP SEQ ID NO:34: Portion of H2 homolog of P. gingivalis DPP SEQIDNO:35: Portion of H3 homolog of P. gingivalis DPP SEQIDNOs:36-37: Probes SEQIDNO:38: Nucleotide sequence of coding region encoding PTP-A. SEQ ID NO:39: Consensus sequence for clan SC where X is any amino acid and S is the active site serine GXSXXG.
- SEQIDNO:40 Consensus sequence for family S9 where X is any amino acid and S is the active site serine GXSXGG.
- SEQIDNO:41 A specific substrate for a prolyl-tripeptidyl peptidase, where
- Xaa represents a natural or modified amino acid residue
- Yaa represents a natural or modified amino acid residue except proline.
- SEQIDNO:42 DPP from P. gingivalis SEQ ID NO:43 HI homolog of P. gingivalis DPP SEQ ID NO:44 H2 homolog of P. gingivalis DPP SEQIDNO:45 H3 homolog of P. gingivalis DPP SEQ ID NO:46 Synthetic peptides SEQIDNO:47 Synthetic peptides SEQIDNO:48 Amino terminal sequence of DPP TV
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU38639/00A AU3863900A (en) | 1999-03-05 | 2000-03-03 | Prolyl peptidases and methods of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12314899P | 1999-03-05 | 1999-03-05 | |
US60/123,148 | 1999-03-05 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000052147A2 WO2000052147A2 (en) | 2000-09-08 |
WO2000052147A3 WO2000052147A3 (en) | 2001-04-12 |
WO2000052147A9 true WO2000052147A9 (en) | 2001-11-01 |
Family
ID=22406979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/005551 WO2000052147A2 (en) | 1999-03-05 | 2000-03-03 | Bacterial prolyl peptidases and methods of use |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3863900A (en) |
WO (1) | WO2000052147A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875851B1 (en) | 1999-03-05 | 2005-04-05 | University Of Georgia Research Foundation, Inc. | Prolyl tripeptidyl peptidases nucleic acid of Porphyromonas gingivalis |
AU2002225954A1 (en) | 2000-11-08 | 2002-05-21 | The University Of Georgia Research Foundation, Inc. | Dipeptidylpeptidases and methods of use |
AU2003236689A1 (en) * | 2002-06-04 | 2003-12-19 | Dsm Ip Assets B.V. | Protein hydrolysate rich in tripeptides |
FR3042192B1 (en) | 2015-10-09 | 2017-12-08 | Inst Europeen De Biologie Cellulaire | PEPTIDES USEFUL IN THE PREVENTIVE AND CURATIVE TREATMENT OF ALOPECIA |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH025880A (en) * | 1988-06-27 | 1990-01-10 | Sunstar Inc | Dna coding post prolyl peptidase |
-
2000
- 2000-03-03 WO PCT/US2000/005551 patent/WO2000052147A2/en active Application Filing
- 2000-03-03 AU AU38639/00A patent/AU3863900A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000052147A3 (en) | 2001-04-12 |
AU3863900A (en) | 2000-09-21 |
WO2000052147A2 (en) | 2000-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6864363B2 (en) | Dipeptidylpeptidases and methods of use | |
Peng et al. | Purification and characterization of a fibrinolytic enzyme produced by Bacillus amyloliquefaciens DC-4 screened from douchi, a traditional Chinese soybean food | |
Hejazi et al. | Isoaspartyl dipeptidase activity of plant-type asparaginases | |
Banbula et al. | Prolyl tripeptidyl peptidase from Porphyromonas gingivalis: a novel enzyme with possible pathological implications for the development of periodontitis | |
Dubin et al. | Molecular cloning and biochemical characterisation of proteases from Staphylococcus epidermidis | |
Saito et al. | Cloning, expression, and sequencing of a protease gene from Bacteroides forsythus ATCC 43037 in Escherichia coli | |
JP4839215B2 (en) | Novel fungal protein and nucleic acid encoding the same | |
Jeong et al. | Purification and biochemical characterization of a fibrinolytic enzyme from Bacillus subtilis BK-17 | |
US5475097A (en) | Lysine-specific Porphyromonas gingivalis proteinase | |
Kwon et al. | Extracellular alkaline proteases from alkalophilic Vibrio metschnikovii strain RH530 | |
KR100879962B1 (en) | Digestive enzyme composition, thrombolytic agent, food solubilizing agent, food softening agent, meat modifier, aniaml feed additive, food additive and oil/fat seperator containing protease | |
Miyoshi et al. | An exocellular thermolysin-like metalloprotease produced by Vibrio fluvialis: purification, characterization, and gene cloning | |
US5523390A (en) | Porphyromonas gingivalis arginine-specific proteinase | |
Kim et al. | Cloning and sequence analysis of a novel metalloprotease gene from Vibrio parahaemolyticus 04 | |
CA2249994A1 (en) | Immunogenic compositions comprising porphyromonas gingivalis peptides and methods | |
Madden et al. | Revised sequence of the Porphyromonas gingivalis prtT cysteine protease/hemagglutinin gene: homology with streptococcal pyrogenic exotoxin B/streptococcal proteinase | |
US6875851B1 (en) | Prolyl tripeptidyl peptidases nucleic acid of Porphyromonas gingivalis | |
Harwood et al. | Overexpression and characterization of a prolyl endopeptidase from the hyperthermophilic archaeon Pyrococcus furiosus | |
Massaoud et al. | Enzymatic characterization of a serralysin-like metalloprotease from the entomopathogen bacterium, Xenorhabdus | |
Teo et al. | Cloning and characterization of a metalloprotease from Vibrio harveyi strain AP6 | |
US6274718B1 (en) | Porphyromonas gingivalis arginine-specific proteinase coding sequences | |
Healy et al. | The lysine-specific proteinase from Armillaria mellea is a member of a novel class of metalloendopeptidases located in Basidiomycetes | |
Goldstein et al. | Novel extracellular x-prolyl dipeptidyl-peptidase (DPP) from Streptococcus gordonii FSS2: an emerging subfamily of viridans streptococcal x-prolyl DPPs | |
WO2000052147A9 (en) | Bacterial prolyl peptidases and methods of use | |
Goldstein et al. | Extracellular arginine aminopeptidase from Streptococcus gordonii FSS2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/19-19/19 |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |